In this issue:
Zanubrutinib or ibrutinib for R/R CLL
Obinutuzumab and glofitamab for R/R DLBCL
Risks of rituximab and obinutuzumab for FL patients
Failure of anti-CD19 CAR T-cell therapy – prognostic markers and treatment
Gilteritinib activity in R/R FLT3-mutated AML patients
Prevalence of EBV
High-dose cytarabine and autologous stem-cell transplantation in MCL
Maintenance rituximab in MCL patients
Evaluating a chemotherapy-free strategy
Efficacy and safety of BV-AVD and ABVD
Please login below to download this issue (PDF)